Loading stock data…
Neumora Therapeutics, Inc. (NMRA)
$1.72+0.08 (+4.88%)
Market ClosedLast close Jun 29
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neumora Therapeutics, Inc. in the Healthcare sector is trading at $1.72 with a market capitalization of $322M. Wall Street consensus targets $6.53 (8 analysts), implying a +279.8% move over the next 12 months. The stock is currently 53% below its 52-week high of $3.65, remaining 21.5% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +279.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$52.86M↑ | -$58.48M↓ | -$57.70M↓ | -$54.04M↑ | -$70.94M |
| Net Income | -$53.46M↑ | -$59.45M↓ | -$56.76M↓ | -$52.73M↑ | -$67.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$322.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-314.65%
Volume
Today's trading volume
1.64M
Recent News
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment being tested in patients with major depressive disorder. On May 7, Neumora said two late-stage studies, KOASTAL-2 and KOASTAL-3, were fully enrolled in the first quarter of 2026, […]
Three pivotal MDD trial failures for Neumora lead to staffing cuts
The KOASTAL 2 and KOASTAL 3 trials also failed to meet their endpoints, with Neumora now culling development of the MDD candidate
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
NMRA stock sinks 49% after phase III depression studies show navacaprant's failure to meet key goals, leading to discontinuation of its development.
Neumora depression drug fails; EnGene to cut 50% of staff
Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Monday afternoon with the NYSE Healthcare Index decreasing 0.6% and